Dong-E-E-Jiao Co. (000423) Q2 2025 earnings summary

Executive summary

• Revenue for H1 2025 reached ¥3.05 billion, up 11.02% year-over-year; net profit attributable to shareholders was ¥818 million, up 10.74% year-over-year.

• Core business remains in Ejiao and related traditional Chinese medicine products, with leading market share and strong brand recognition.

• Major products include Ejiao, compound Ejiao oral liquid, Ejiao cake, instant Ejiao powder, and new male health supplements.

• Dividend payout ratio is exceptionally high, with 99.94% of H1 net profit distributed as cash dividends.

Financial highlights

• Operating income: ¥3.05 billion, up 11.02% year-over-year.

• Net profit attributable to shareholders: ¥818 million, up 10.74% year-over-year.

• Basic and diluted EPS: ¥1.2698, up 10.52% year-over-year.

• Operating cash flow: ¥965 million, up 4.70% year-over-year.

• Gross margin for core Ejiao products: 74.83%.

• Total assets at period end: ¥12.78 billion; net assets: ¥10.31 billion.

Outlook and guidance

• Focus on high-quality, sustainable growth and innovation in health supplements and traditional Chinese medicine.

• Continued expansion into male health and new consumer segments.

• Ongoing implementation of “quality and return dual improvement” action plan.